Innovus Pharmaceuticals (Innovus Pharmaceuticals) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2019)

View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals ROE % Adjusted to Book Value?

Innovus Pharmaceuticals's ROE % for the quarter that ended in Sep. 2019 was 0.00%. Innovus Pharmaceuticals's PB Ratio for the quarter that ended in Sep. 2019 was N/A. Innovus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2019 was N/A.

Innovus Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Innovus Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovus Pharmaceuticals ROE % Adjusted to Book Value Chart

Innovus Pharmaceuticals Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-191.52

-42.05

-12.03

Innovus Pharmaceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-33.20	-13.14	-111.66	-15.05	-

Competitive Comparison of Innovus Pharmaceuticals's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Innovus Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovus Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Innovus Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Innovus Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Innovus Pharmaceuticals ROE % Adjusted to Book Value Calculation

Innovus Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2018 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-1,636.17%	/	135.96
	=	-12.03%

Innovus Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2019 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Innovus Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

8845 Rehco Road, San Diego, CA, USA, 92121

Website

http://www.innovuspharma.com

Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.

Executives

Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu	director
Henry Jemil Esber	director	38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz	officer: EVP, CORPORATE DEVELOPMENT	6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn	officer: VP, CFO	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj	director, officer: CHIEF EXECUTIVE OFFICER	C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman	officer: Chief Financial Officer	ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown	officer: See remarks	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew	director	175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness	director, officer: Secretary	175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack	director, 10 percent owner, officer: President & CEO	175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111